@taylormaemcd's injection site advice, fact-checked
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates. The STEP and SURMOUNT trials used rotation between these sites and showed 15-20% average weight loss over 68-72 weeks.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
TikTok creator @taylormaemcd tells her 127K viewers that injecting "above the belly button" is her "#1 place" for GLP-1 medications. She's promoting her partnership with Amble Health while sharing injection site preferences.
The video doesn't make specific medical claims about why this location is superior. It's more of a personal recommendation wrapped in wellness influencer marketing speak.
Does injection location actually matter for GLP-1s?
Yes, but probably not how you'd think. The SUSTAIN trials for semaglutide tested subcutaneous injections in the abdomen, thigh, and upper arm without finding meaningful differences in drug absorption or efficacy.
What matters more is rotating injection sites to prevent lipodystrophy (fatty tissue changes). The STEP trials, which showed 14.9% weight loss with 2.4mg semaglutide, used multiple injection sites throughout the studies.
Taylor's preference for above the belly button falls within FDA-approved abdominal injection areas. But calling it the "#1 place" oversells what the data actually shows.
What about the Amble Health partnership?
This is where things get murky. Taylor's promoting a telehealth platform while giving injection advice, which blurs the line between personal experience and sponsored content.
The FTC requires clear disclosure when health advice comes with financial incentives. While she includes #ambleptnr (presumably "Amble partner"), it's buried among 13 hashtags.
Telehealth platforms like Amble can provide legitimate GLP-1 prescriptions, but injection technique should come from your prescribing provider, not sponsored content.
What should you actually know about injection sites?
Stick to the basics that work. Novo Nordisk's prescribing information for Wegovy lists abdomen, thigh, and upper arm as equally effective sites.
Rotate locations within each area to prevent tissue damage. The clinical trials that proved these medications work used systematic rotation, not one "favorite" spot.
Your healthcare provider should demonstrate proper injection technique during your first visit. Don't rely on TikTok for medical procedures, even seemingly simple ones.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @taylormaemcd's injection site advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@taylormaemcd's injection site advice, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates. The STEP and SURMOUNT trials used rotation between these sites and showed 15-20% average weight loss over 68-72 weeks.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates. The STEP and SURMOUNT trials used rotation between these sites and showed 15-20% average weight loss over 68-72 weeks.
- Clinical trials found no meaningful differences between FDA-approved injection sites (abdomen, thigh, upper arm)
- The STEP 1 trial achieved 14.9% weight loss using multiple injection sites, not one preferred location
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Clinical trials found no meaningful differences between FDA-approved injection sites (abdomen, thigh, upper arm)
- The STEP 1 trial achieved 14.9% weight loss using multiple injection sites, not one preferred location
- Site rotation prevents lipodystrophy and tissue damage more effectively than using one "favorite" spot
- Sponsored injection advice from influencers shouldn't replace guidance from prescribing healthcare providers
- FTC guidelines require clear disclosure when health advice comes with financial partnerships
- Telehealth platforms can legitimately prescribe GLP-1s but proper injection training should come from medical professionals
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Taylor Mae • Wellness ✨ · TikTok creator
127.4K views on this video
back to above the belly button! my #1 place ✨ 🔗 in my bio to start your journey! #glp #glp1forweightloss #glp1medication #glp1girlies #glp1forpcos #pcos #taylormaemcd #glp1community #glp1journey #amb
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Taylor Mae • Wellness ✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.